About Mirum Pharma
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its focuses on diseases for which the unmet medical need is high and the biology for treatment is clear. Its pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a range of orphan liver diseases. The Company initially developing maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis (PFIC), and Alagille syndrome (ALGS). It has commenced enrollment in the Phase III clinical trial in PFIC and planning to initiate a Phase III clinical trial in ALGS. The Company is developing volixibat for the treatment of adult patients with cholestatic liver diseases including primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy (ICP) and primary biliary cholangitis (PBC).